MASLD patients have increased levels of enzymes governing glycolysis which lead to enhanced glycolytic capacity such as hexokinase 2 (HK2) and pyruvate kinase isozyme type M2 (PKM2). This evidence concerns the gene HK2 and metabolic dysfunction-associated steatotic liver disease.